IOL Chemicals and Pharmaceuticals Limited — Investor Meet, 26-11-2024: Analysts/Institutional Investor Meet/Con. Call Updates

1. **Financial Performance:** IOL Chemicals and Pharmaceuticals reported total income of ₹532 crore for Q2 FY2025, down from ₹552 crore in Q2 FY2024 and compared to ₹510 crore in Q1 FY2025. EBITDA decreased to ₹48 crore, reflecting a margin of 9%, down from 12.9% in the same quarter last year. Net profit fell to ₹19 crore versus ₹38 crore year-on-year and ₹30 crore sequentially. The pharmaceutical segment's EBIT margin stands at 8.4%, highlighting pressure due to pricing changes.

2. **Future Outlook and Growth Drivers:** Management is optimistic about the long-term potential of the API business, particularly in specialty chemicals like ethyl acetate, driven by rising demand from pharmaceuticals and other industries. The acquisition of 101 acres for a new manufacturing facility positions the company for expansion.

3. **Order Book and Operational Updates:** The company reported an increase in exports to ₹140 crore in Q2 FY2025 from ₹130 crore in the same period last year. The CAPEX for the quarter rose to ₹83 crore, showing commitment to growth initiatives.

4. **Analyst Q&A Insights (Detailed):**

- **Revenue and Profitability:** Management clarified that rising employee costs were due to variable pay and capacity expansion for non-ibuprofen products.

- **Market Position and Competitive Landscape:** Analysts sought clarity on the non-ibu product export strategy, with management aiming for 50% non-ibu exports in 2-3 years, up from 24%.

- **Operational Challenges or Risks:** The management acknowledged the impact of current pricing dynamics on profitability, particularly around ibuprofen.

- **Capex and Capital Allocation:** Plans to operationalize the new land by FY2026, though specifics on future CAPEX were pending.

- **Strategic Priorities and Long-Term Vision:** Management focuses on stabilizing current products while strategizing for regulatory markets to improve revenue streams.

5. **Market or Regulatory Updates:** The company anticipates stable pricing and demand recovery for major products, despite prior volatility.

6. **Strategic Focus Areas:** There is a clear emphasis on expanding production capabilities, improving operational efficiencies, and capturing growth in regulated markets.

7. **Investor Insight:** While the financial results show challenges, particularly with margin compression, the strategic initiatives in expanding facilities and targeting global markets suggest a cautious optimism. This positions the stock in a potential ‘buy’ scenario, considering the overall growth strategy and market recovery signals.